To evaluate the protective effects of bortezomib (Velcade) on ischemia-reperfusion (IR) injury in the rat retina.
The rats were randomized to receive treatment with saline, low-dose bortezomib (0.05 mg/kg), or high-dose bortezomib (0.2 mg/kg) before the induction of IR injury. Electroretinography (ERG) was used to assess functional changes in the retina. The expression of inflammatory mediators (iNOS, ICAM-1, MCP-1, TNF-α), anti-oxidant proteins (heme oxygenase, thioredoxin, peroxiredoxin), and pro-apoptotic proteins (p53, bax) were quantified by PCR and western blot analysis. An immunofluorescence study was performed to detect the expression of iNOS, oxidative markers (nitrotyrosine, 8-OHdG, acrolein), NF-κB p65, and CD 68. Apoptosis of retinal cells was labeled with in situ TUNEL staining. Neu-N staining was performed in the flat-mounted retina to evaluate the density of retinal ganglion cells.
ERG showed a decreased b-wave after IR injury, and pretreatment with bortezomib, especially the high dosage, reduced the functional impairment. Bortezomib successfully reduced the elevation of inflammatory mediators, anti-oxidant proteins, pro-apoptotic proteins and oxidative markers after IR insult in a dose-dependent manner. In a similar fashion, NF-κB p65- and CD 68-positive cells were decreased by bortezomib treatment. Retinal cell apoptosis in each layer was attenuated by bortezomib. The retinal ganglion cell density was markedly decreased in the saline and low-dose bortezomib groups but was not significantly changed in the high-dose bortezomib group.
Citation: Chen F-T, Yang C-M, Yang C-H (2013) The Protective Effects of the Proteasome Inhibitor Bortezomib (Velcade) on Ischemia-Reperfusion Injury in the Rat Retina. PLoS ONE 8(5): e64262. https://doi.org/10.1371/journal.pone.0064262
Editor: Rajesh Mohanraj, UAE University, Faculty of Medicine & Health Sciences, United Arab Emirates
Received: January 24, 2013; Accepted: April 11, 2013; Published: May 14, 2013
Copyright: © 2013 Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing interests: The authors have declared that no competing interests exist.
Ischemia-reperfusion (IR) injury is caused by transient disruption of blood supply in tissues followed by reperfusion. This phenomenon contributes to various clinical problems after stroke, myocardial infarction, shock, and organ transplantation. Emerging evidence suggests that IR injury is also implicated in the pathogenesis of several vision-threatening ophthalmic disorders, such as retinal vascular occlusive disease, glaucoma and diabetic retinopathy –. The postulated pathophysiologic mechanisms of ischemic cell injury include depletion of adenosine triphosphate (ATP) and disturbance of intracellular calcium homeostasis, which results in cell death . Furthermore, the reperfusion status aggravates the tissue insult because of released reactive oxygen species and proinflammatory mediators, which recruit inflammatory cells into tissues –.
The retinal ischemia-reperfusion (IR) state of a rat can be accomplished by increasing the intraocular pressure through cannulation of the eye to interfere with retinal circulation followed by natural reperfusion , . Electroretinography (ERG) showed a decreased a-wave and b-wave after the ischemic event, with the b-wave predominantly affected. Histologically, the IR model was shown to cause apoptosis in retinal neurons and decreased thickness in retinal cell layers, especially in the inner retinal layer –. Consistent with TUNEL staining results for apoptotic neurons in the inner nuclear layer, increased caspase-3 was also observed . Several inflammatory and neurodegenerative processes in the retina have been observed in this animal model . Increased inflammatory mediators, such as TNF-α, IL-1β, IL-6, IL-10, CCL-2 (MCP-1), CCL-5 (RANTES), CXCL-10, ICAM-1, VCAM-1, and iNOS, were noted in several studies. Notably, NF-κB is crucial for up-regulating these inflammation-associated genes , , –.
NF (nuclear factor)-κB, a ubiquitous transcription factor, is involved in the expression of many genes associated with inflammation, cell injury and stress, and it also plays an important role in the regulation of cell survival and death. NF-κB may also be a pivotal factor in the IR injury of organs –. Several experimental studies have demonstrated an increased expression of activated NF-κB after retinal IR injury , , . NF-κB consists of two subunits, p50 and p65 (RelA), and its activation depends on the ubiquitin-proteasome system (UPS), the major non-lysosomal pathway for intracellular protein degradation to maintain several basic cellular functions, including cell cycle progression, the stress response, and apoptosis –. Under normal conditions, NF-κB is bound to its inhibitory factor, IκB, and the complex is present in the cytosol. Certain stimuli, such as inflammatory signals and oxidative stress, can trigger the phosphorylation of IκB and lead to the ubiquitination and degradation of IκB by the proteasome. After dissociating from IκB, the active form of NF-κB translocates into the nucleus and promotes the transcription of related genes , .
Proteasome inhibitors have been demonstrated to be beneficial in several pathologic conditions, including autoimmune disorders in animal models and cancers in human , . Proteasome inhibitors are also shown to have organ-protective effects in experimental IR injury of the brain, heart and kidney –. Blockage of NF-κB activation is thought to account for the majority of protective effects by proteasome inhibition. The effect of proteasome inhibitors on retinal IR injury has never been studied. Bortezomib (Velcade), previously known as PS-341, LDP-341 and MLM341, is a 26S proteasome inhibitor. It is approved by the FDA for use in the treatment of multiple myeloma . We have demonstrated that bortezomib had anti-inflammatory effects in endotoxin-induced uveitis of rats in a previous study . Concerning retinal IR injury, we hypothesized that bortezomib could inhibit the activation of NF-κB and associated inflammatory mediators, alleviate oxidative stress in the retina and reduce retinal neuron death and ganglion cell apoptosis. To provide evidence for these predictions, we designed an animal study to investigate the effect of bortezomib on pressure-induced IR injury in the rat retina.
We used 8-week-old, male Sprague-Dawley rats that weighed 200–250 g. The rats were injected with drugs or vehicle intraperitoneally 30 minutes prior to the induction of IR injury. The rats were randomly assigned into one of four groups:
- The control group (sham-operated group): no drug or vehicle was given, and the anterior chamber was penetrated by needle without elevating the intraocular pressure;
- The saline group: injection of PBS before inducing retinal ischemia;
- The bortezomib (L) group: injection of a low dose of bortezomib (0.05 mg/kg; Millennium Pharmaceuticals, Cambridge, MA) before inducing retinal ischemia; and
- The bortezomib (H) group: injection of a high dose of bortezomib (0.2 mg/kg) before inducing retinal ischemia.
Total number of animals used in each group of the experiments was summarized in Table 1. The treatment was blinded to the experimenter.
All experiments were performed in compliance with a protocol approved by the Institutional Animal Care and Use Committee of National Taiwan University and with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.
Pressure-induced Ischemia-reperfusion Injury in the Retina and Tissue Retrieval
Under deep anesthesia with zolazepam+tiletamine (Zoletil 50; Virbac Laboratories, Carros, France) (25 mg/kg) and xylazine (Rompun; Bayer Inc., Toronto, Canada) (5 mg/kg), the anterior chamber of one eye in each rat was cannulated with a 30-gauge needle connected to a saline infusion bottle, and the bottle was elevated to a 180-cm height to achieve a 130-mmHg pressure intraocularly. The ischemic effect was confirmed by the presence of retinal blanching. The pressure was held for 45 minutes, followed by removal of the needle to regain natural reperfusion of the retina.
Some rats in each group were euthanized at 24 hours after reperfusion by intracardiac injection of phenobarbital (25 mg/kg) under deep anesthesia, and the remaining rats received a booster injection of drugs or vehicles after 3 days and were sacrificed on Day 7. The eyeballs were extracted and processed immediately for further evaluation.
The ERG was performed at 24 hours and 7 days after retinal reperfusion, and the rats were kept in the dark room for 24 hours before the examination. The rats were subjected to measurement of ERG waves under deep anesthesia in a room with dim light only. To normalize the data, a relative b-wave ratio indicative of the b-wave amplitude in the normal eye compared to that in the IR-injured eye of the same individual was calculated and used for statistical analysis.
Semi-quantitative Polymerase Chain Reaction (PCR)
Twenty-four hours after the IR injury, some rats in each group were euthanized for determination of the expression of iNOS, ICAM-1, MCP-1, heme oxygenase, thioredoxin, and peroxiredoxin in the retina. Total RNA in the retina was extracted with TRIzol reagent (Invitrogen-Life Technologies, Inc., Gaithersburg, MD). One microgram of total RNA from each sample was annealed with 300 ng oligo (dT) (Promega, Madison, WI) for 5 minutes at 65°C and reverse-transcribed into cDNA using 80 U Moloney murine leukemia virus reverse transcriptase (MMLV-RT; Invitrogen-Gibco, Grand Island, NY) per 50-µg sample for 1 hour at 37°C. The reaction was halted by increasing the temperature to 90°C for 5 minutes. The cDNA product from each sample was subjected to PCR with specific primers (Table 2). The 50-µL reaction mixture contained 5 µL cDNA, 1 µL sense and antisense primers, 200 µM of each deoxynucleotide, 5 µL of 10× Taq polymerase buffer, and 1.25 U Taq polymerase (Promega). Amplification was performed in a thermocycler (MJ Research, Waltham, MA) with a 1-minute denaturation at 94°C and a 3-minute extension at 72°C. The annealing temperature was between 62°C and 42°C, and the temperature was decreased in 1°C increments, followed by 21 cycles at 55°C. Finally, the temperature was elevated to 72°C for 10 minutes and then reduced to 4°C. We obtained a 10-µL sample of each PCR product to perform electrophoresis on 2% agarose gels containing ethidium bromide (Sigma-Aldrich). The results were analyzed under ultra-violet light using DNA molecular length markers. The intensity was quantified using image analysis software (Photoshop, ver.7.0; Adobe Systems, San Jose, CA), and the results were standardized against the intensity of rat β-actin, a housekeeping gene.
Western Blot Analysis
For the rats sacrificed at 24 hours after retinal reperfusion, total protein was extracted from the retina by lysing the sample in radioimmunoprecipitation assay (RIPA) buffer [0.5 M Tris-HCl (pH 7.4), 1.5 M NaCl, 2.5% deoxycholic acid, 10% NP-40, 10 mM EDTA and protease inhibitors (Complete Mini; Roche Diagnostics Corp., Indianapolis, IN)]. The extract and Laemmli buffer were mixed at a 1∶1 ratio, and the mixture was boiled for 5 minutes. A 100-µg sample was separated on 10% SDS-polyacrylamide gels and then transferred to polyvinylidene difluoride membranes (Immobilon-P; Millipore Corp., Billerica, MA). The membranes were incubated with anti-iNOS, anti-ICAM-1, anti-TNF-α, anti-p53, anti-bax, and anti-β-actin antibodies. Then, the membranes were incubated with horseradish peroxidase-conjugated secondary antibody and visualized by chemiluminescence (GE Healthcare). The density of blots was determined using image-analysis software after scanning the image (Photoshop, ver.7.0; Adobe Systems, San Jose, CA). The optical densities of each band were calculated and standardized based on the density of the β-actin band.
Immunofluorescence (IF) Stain of the Retina
Twenty-four hours after IR injury of the retina, the eyeballs were enucleated and immersed in 4% paraformaldehyde in 0.2 M phosphate buffer for 24 hours. After fixation, the eyes were dehydrated with alcohol and then embedded in paraffin. The specimens were cut into 5-µm sagittal sections near the optic nerve head to evaluate the expression of iNOS, nitrotyrosine, 8-OHdG, acrolein, NF-κB p65, and CD 68 in the retina.
After deparaffinization with xylene solutions and rehydration with a graded series of ethanol in PBS, the tissue sections were incubated overnight with monoclonal antibodies against iNOS, nitrotyrosine, 8-OHdG, acrolein, CD 68 (Santa Cruz Biotechnology, Santa Cruz, CA) and the p65 subunit of NF-κB (Chemicon, Temecula, CA) separately at 4°C. The immunoreactivity was detected by adding a rhodamine-labeled (for CD 68) or fluorescein isothiocyanate (FITC)-labeled (for the others) secondary antibody (Abcam, Cambridge, U.K.), and the cell nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI). Specimens stained without the primary antibody were used as negative controls.
In situ TdT-mediated dUTP Nick-end Labeling (TUNEL) Assay
Retinal cell apoptosis was determined by TUNEL assay at 24 hours after the IR injury. The retinal sections were stained using a TUNEL-based kit (TdT FragEL; Oncogene, Darmstadt, Germany) according to the manufacturer’s instructions. The sections incubated with DNase I prior to the labeling procedure were used as positive controls, and the sections stained with label solution containing no terminal transferase were used as negative controls.
NeuN Stain in Flat-mounted Retina and Counting of NeuN-positive Cells
The density of retinal ganglion cells (RGCs) was evaluated by immunofluorescence staining with NeuN 7 days after retinal reperfusion. Briefly, the eyeballs were incised at the ora serrata and immersion-fixed in a 4% paraformaldehyde solution for 1 h, and the retina tissues were extracted. The retina was cryoprotected overnight in 30% sucrose followed by three freeze–thaw cycles and incubated overnight with monoclonal FITC-conjugated NeuN antibody (Chemicon, USA). Finally, the retina was flat-mounted and viewed with a Leica TSL AOBS SP5 confocal microscope (Leica Microsystems, Exton, PA, USA).
The number of NeuN-positive cells for each retinal section was counted in 4 selected retinal areas located at the same eccentricity (approximately 1.5 mm from the optic disk) in the four retinal quadrants. The cell number was quantified with image-analysis software (Image-Pro Plus, ver.6.0; Mediacybernetic, Atlanta, GA, USA).
Measurement of Proteasome Activity in the Retina
The chymotrypsin-like activity of the proteasome in the rats sacrificed at 24 hours after retinal reperfusion was determined using commercial proteassome assay kits (Proteasome-Glo™ assay systems; Promega) according to the manufacturer’s instructions. Briefly, the Suc-LLVY-Glo™ substrate was added to the mixture of the Proteasome-Glo™ buffer and the luciferin detection reagent and incubated at room temperature for 1 hour. The retinal tissue was minced in 100 µL of ice-cold buffer PBS containing 5 mM EDTA followed by centrifugation at 12000 g at 4°C for 10 minutes. A 50-µL retinal sample was added by equal volume of reagent mixture and incubated for 1.5 hours. Finally, the luminescence of retinal sample was detected by a microplate luminometer (Promega).
The Effect of Bortezomib on Retinal Functional Change following IR Injury
The relative b-wave ratio was approximately equal to 1 in the normal controls. For the IR-injured rats, whether pretreated with saline, low-dose bortezomib or high-dose bortezomib, the ratios were all significantly decreased, both at 24 hours and 7 days after injury (P<0.05 in all paired comparisons with normal rats). Notably, in rats pretreated with high-dose bortezomib, the relative b-wave ratio was higher than that in the saline and the low-dose bortezomib groups, both at 24 hours (P = 0.001 and P = 0.002) and 7 days (P = 0.021 and P = 0.014) after the IR injury (Figure 1).
The relative b-wave ratio was significantly decreased in the saline, low-dose bortezomib [Vel (L)] and high-dose bortezomib [Vel (H)] groups compared with the control group, both at 24 hours and 7 days after injury. Notably, the relative b-wave ratio in the high-dose bortezomib [Vel (H)] group was significantly higher than that in the saline and low-dose bortezomib [Vel (L)] groups in time-matched comparisons. The data are expressed as the mean ± SD of the mean in 6 rats for each group (bar graph). *P<0.05 compared with the control group. #P<0.05 by Kruskal Wallis H test with post hoc Dunn test.
The Effect of Bortezomib on the mRNA Expression of Inflammatory Mediators and Anti-oxidant Proteins in IR-injured Retinas
The mRNA expression levels of iNOS, ICAM-1 and MCP-1 were significantly higher in the IR-injured rats pretreated with saline compared with normal rats (P<0.05 in all paired comparisons). In the IR-injured rats pretreated with low- or high-dose bortezomib, the expression of these inflammatory mediators was significantly lower than that in the saline group (P<0.05 in all paired comparisons). In addition, the levels of ICAM-1 and MCP-1 were more reduced in the high-dose bortezomib group than in the low-dose bortezomib group (P = 0.004 and <0.001, respectively) (Figure 2A, 2B, 2C).
The mRNA expression levels of iNOS (A), ICAM-1 (B) and MCP-1 (C) were significantly higher in the saline, low-dose bortezomib [Vel (L)] and high-dose bortezomib [Vel (H)] groups compared with normal rats. The expression of these inflammatory mediators was significantly lower in the bortezomib-pretreated groups, especially in the high-dose group, than in the saline group. The mRNA expression levels of heme oxygenase (C), thioredoxin (D) and peroxiredoxin (E) were significantly higher in the saline group compared with the control group. The expression of these anti-oxidant proteins was significantly lower in the bortezomib-pretreated groups than in the saline group, and the levels of thioredoxin and peroxiredoxin did not differ significantly between the high-dose bortezomib and control groups. The data are expressed as the mean ± SD of the mean in 5 rats for each group (bar graph). *P<0.05 compared with the control group. #P<0.05 compared with the saline group. & P<0.05 by Kruskal Wallis H test with post hoc Dunn test.
In a similar fashion, the mRNA expression levels of heme oxygenase, thioredoxin and peroxiredoxin were significantly higher in the saline group compared with the control group (P<0.05 in all paired comparisons). The expression of these anti-oxidant proteins was significantly lower in the bortezomib groups than in the saline group (P<0.05 in all paired comparisons), and the levels of thioredoxin and peroxiredoxin did not differ significantly between the high-dose bortezomib and control groups (P = 0.900 and 0.970, respectively) (Figure 2D, 2E, 2F).
The Influence of Bortezomib on the Levels of Inflammatory Mediators and Pro-apoptotic Proteins in IR-injured Retinas
The protein levels of iNOS, ICAM-1, MCP-1 and TNF-α were significantly higher in the IR-injured rats pretreated with saline compared with normal rats (P<0.001 in all paired comparisons). In the IR-injured rats pretreated with low- or high-dose bortezomib, these inflammatory mediators were significantly lower than in the saline group (P<0.05 in all paired comparisons). In addition, the levels of iNOS, ICAM-1 and MCP-1 were more reduced in the high-dose bortezomib group than in the low-dose bortezomib group (P<0.05 in all paired comparisons) (Figure 3A, 3B, 3C and 3D).
The protein levels of iNOS (A), ICAM-1 (B), MCP-1 (C) and TNF-α (D) were significantly higher in the saline group compared with normal rats. In the bortezomib-pretreated groups, especially in the high-dose group, the levels of inflammatory mediators were significantly lower than in the saline group. The levels of p53 (E) and bax (F) were significantly higher in the saline group compared with the control group. The expression levels of p53 and bax were lower in the bortezomib-pretreated groups, especially in the high-dose group, compared with the saline group. The data are expressed as the mean ± SD of the mean in 5 rats for each group (bar graph). *P<0.05 compared with the control group. #P<0.05 compared with the saline group. & P<0.05 by Kruskal Wallis H test with post hoc Dunn test.
The levels of p53 and bax were significantly higher in the saline group compared with the control group (P<0.05 in all paired comparisons). The expression levels of p53 and bax were lower in the bortezomib group compared with the saline group, and the differences were statistically significant in the high-dose bortezomib group (P<0.001 in all paired comparisons) (Figure 3E and 3F).
The Effect of Bortezomib on the Expression of iNOS and Oxidative Markers in IR-injured Retinas
IF staining revealed marked expression of iNOS in each retinal layer in the saline group compared with the control group. In rats pretreated with bortezomib, the expression of iNOS was less prominent, especially in the high-dose bortezomib group (Figure 4A).
There was marked expression of iNOS (A) in each retinal layer in the saline group compared with the control group. In the bortezomib-pretreated groups, the expression of iNOS was less prominent, especially in the high-dose bortezomib [Vel (H)] group. Increased staining of nitrotyrosine (B), 8-OHdG (C), and acrolein (D) was noted in the saline group compared with the control group, and expression of these oxidative markers were less prominent in the bortezomib-pretreated groups, especially in the high-dose bortezomib group [Vel (H)]. The images represent three rats in each group. There was little variation between eyes in the same group.
In a similar fashion, increased expression levels of nitrotyrosine, 8-OHdG, and acrolein in the retina were noted in the saline group compared with the control group, and the expression levels of these oxidative markers were less pronounced in the bortezomib groups, especially in the high-dose bortezomib group (Figure 4B, 4C and 4D).
The Inhibitory Effect of Bortezomib on NF-κB Activation in Retinal IR Injury
Increased staining of the NF-κB p65 subunit in each layer of the retina was noted in the saline group and low-dose bortezomib group. In contrast, there was no significant difference in p65 expression between the high-dose bortezomib group and the control group (Figure 5).
There was increased staining of the NF-κB p65 subunit in the retinal layer in the saline group and the low-dose bortezomib group [Vel (L)] but not in the high-dose bortezomib group [Vel (H)]. The images represent three rats in each group. There was little variation between eyes in the same group.
Bortezomib Reduced the Recruitment of CD 68 Cells in IR-injured Retinas
Normally, nearly no CD 68-positive cells were present in the retina. Some CD 68 cells were noted in the inner retinal tissue in the saline group, as well as in the low-dose bortezomib group. However, in the high-dose bortezomib group, no CD 68 cells were found in the retinal sections (Figure 6).
No CD 68-positive cells were found in the control group. Some CD 68 cells were noted in the inner retina in the saline group, as well as in the low-dose bortezomib group [Vel (L)]. However, no CD 68 cells were found in the high-dose bortezomib group [Vel (H)]. The images represent three rats in each group. There was little variation between eyes in the same group.
The Anti-apoptotic Effect of Bortezomib on IR-injured Retinas
Increased cell apoptosis in each retinal layer was noted in the saline group compared with the control group by in situ TUNEL staining. In the IR-injured rats pretreated with bortezomib, especially in the high dosage group, the density of TUNEL-positive cells was markedly reduced compared with rats pretreated with saline (Figure 7).
TUNEL-positive nuclei in each layer of retinal tissue were noted in the saline group but not in the control group (Ctrl). In the bortezomib-pretreated groups, especially in the high-dose group (Vel-High), the density of TUNEL-positive cells was markedly reduced compared with the saline group. The images represent three rats in each group. There was little variation between eyes in the same group. Positive: positive controls: tissue sections incubated with DNase I prior to the labeling procedure. Negative: negative controls: tissue sections stained with label solution containing no terminal transferase.
The Influence of Bortezomib on the Density of Retinal Ganglion Cells in IR-injured Retinas
Decreased numbers of retinal ganglion cells were noted in the saline and the low-dose bortezomib groups compared with those in the control group by Neu-N IF staining (P = 0.005 and 0.028, respectively). However, there was no difference in the numbers of retinal ganglion cells between the high-dose bortezomib group and the control group (P = 0.989) (Figure 8).
Compared with the control group, there were significantly decreased numbers of retinal ganglion cells in the saline and the low-dose bortezomib [Vel (L)] groups but not in the high-dose bortezomib group [Vel (H)]. The images represent three rats in each group. There was little variation between eyes in the same group. The data are expressed as the mean ± SD of the mean in 3 rats for each group (bar graph). *P<0.05 compared with the control group. #P<0.05 by Kruskal Wallis H test with post hoc Dunn test.
The Effect of Bortezomib on Chymotrypsin-like Activity of the Proteasome in IR-injured Retinas
Increased signal of luminescence, indicating increased chymotrypsin-like activity, in the retinal tissues was noted in the saline group compared with the control group. The signals were significantly lower in the bortezomib-pretreated groups than in the saline group. There was no significance difference in the signal of luminescence between the low-dose and the high-dose bortezomib groups (P = 0.125) (Figure 9).
Compared with the control group, there was significantly increased signal of luminescence in the saline, the low-dose [Vel (L)], and the high-dose bortezomib [Vel (H)] groups. The signals were markedly lowered in the bortezomib-pretreated groups compared with the saline group. No statistically significant difference was observed between the low-dose and the high-dose bortezomib groups. The data are expressed as the mean ± SD of the mean in 5 rats for each group (bar graph). *P<0.05 compared with the control group. #P<0.05 by Kruskal Wallis H test with post hoc Dunn test.
There was no mortality or extraocular morbidity associated with the induction of IR injury or the treatment in the experimental animals. The body weight and the number of the red blood cell (RBC) and white blood cell (WBC) of the rats did not differ significantly between the control and the treated groups both at 24 hours and on Day 7 (Figure S1, S2).
Our study demonstrated that pretreatment with bortezomib could dose-dependently reduce the b-wave decrement in ERG, and PCR and western blot analysis showed that pretreatment with bortezomib could decrease the expression of inflammatory mediators and production of p53 and bax. IF staining of retinal sections revealed that bortezomib decreased tissue oxidative stress, activation of NF-κB and recruitment of CD 68 cells resulting from IR insult. We observed that cell apoptosis, revealed by in situ TUNEL staining, was attenuated by bortezomib. IF staining with Neu-N indicated that retinal ganglion cells were largely preserved in the high-dose bortezomib group after 7 days of initiating IR injury.
Currently, the clinical application of bortezomib is primarily in the treatment of human hematologic diseases, such as multiple myeloma, mantle cell lymphoma, and acute graft-versus-host disease after allograft bone marrow transplantation , . Other potential applications of bortezomib, such as the anti-inflammatory effects in autoimmune diseases and the protective effects in IR injury of brain, heart, and kidney –, , , , are under investigation and currently limited to use in animal models. Although not fully understood, the postulated mechanism of the drug’s effect is primarily achieved through the inhibition of NF-κB activation, which in turn reduces the transcription of inflammation-related genes and avoids the induction of inflammatory cascades. Therefore, a proteasome inhibitor could protect target tissues from inflammation-induced oxidative stress and cell damage.
Whether proteasome function is altered in the process of IR injury is still controversial. Increased proteasome activity has been observed in an experimental study of IR injury in liver tissue, as well as in the retina demonstrated by our study . Moreover, proteasome inhibitors theoretically normalize the proteasome function and exert anti-inflammatory effects through the inactivation of NF-κB. However, impaired proteasome function has been found in some animal studies of IR injury in brain and heart tissue. A plausible explanation for this impairment is the depletion of ATP during ischemia, which inhibits the conversion of 20S to 26S proteasome. Another possibility is that the oxidative protein and lipid products interfere with the enzyme activity of proteasomes. Furthermore, the functional impairment of proteasomes will lead to the intracellular accumulation of oxidative and ubiquitinated proteins, resulting in a vicious cycle –. Paradoxically, the use of proteasome inhibitors in these animal models has been demonstrated to lead to a tissue-protective effect, which may be related to the time of drug administration. It has been postulated that short-term use of proteasome inhibitors in the acute stage of IR injury, during which the proteasome function was only minimally affected, may be more beneficial than persistent use of the drug in the chronic stage .
Our study demonstrated that the activation of NF-κB was involved in the pathogenesis of IR injury in the retina, which was compatible with the results of other animal studies , , , . In these studies, the activation of NF-κB was found to peak at 12 to 24 hours after the injury , . Furthermore, several studies have demonstrated that the activation of NF-κB was associated with an increased expression of inflammatory mediators, including TNF-α, MCP-1 (CCL2), ICAM-1, VCAM-1, and iNOS, after retinal IR injury. These studies also showed that inhibition of NF-κB could reduce the cell damage , –, . Increased levels of TNF-α were observed in the early stage of retinal ischemia and in several neurodegenerative diseases, and TNF-α was proposed as a pivotal cytokine mediating neuron death –. MCP-1 is an important chemokine in attracting monocytes/macrophages to target tissues . TNF-α is one of the cytokines responsible for up-regulation of ICAM-1 expression in endothelial cells of blood vessels to facilitate leukocyte adhesion and transmigration into interstitial space –. As a result, the increase of inflammatory cells can lead to occlusion of the capillaries in local tissue, which further augments the ischemic insult. Further oxidative products are generated, and severe tissue damage ensues . In addition, increased expression of iNOS in infiltrating leukocytes and inner retinal layer occurs after retinal ischemia, and the increased production of NO, a cytotoxic free radical, results in neural cell death by impairing oxidative enzyme activity, leading to the formation of oxidative products, and directly attacking DNA , –. Our experiment demonstrated that bortezomib could inhibit the NF-κB activation after retinal IR injury and decrease the expression of TNF-α, MCP-1, ICAM-1 and iNOS. Bortezomib also inhibited the infiltration of CD 68 (a cell marker of microglia/macrophages)-positive cells and decreased the expression of oxidative markers, including nitrotyrosine, 8-OHdG and acolein, in retinal tissue. Decreased production of anti-oxidant proteins, including heme oxygenase-1, thioredoxin, and peroxiredoxin, presumably occurred because the drug decreased oxidative stress with less induction of these anti-oxidant proteins.
Several studies indicated that oxidative stress is one of the most important causes of retinal neuron death after IR injury and demonstrated that the damage can be alleviated by decreasing oxidative stress –. Decreasing the production of free radicals could reduce the activation of NF-κB and down-regulate the expression of TNF-α, which is the ligand for the TNFR-1/Fas-mediated extrinsic pathway of apoptosis . In addition, the activated NF-κB could promote cell apoptosis by up-regulating p53 expression and interrupting the balance between bax and bcl-xL/bcl-2 –. Therefore, inhibition of NF-κB may protect cells from apoptosis by decreasing p53 expression. Our study demonstrated that bortezomib could reduce the inflammation response and oxidative stress after retinal IR injury. In addition, the expression of p53 and bax was reduced, retinal cell apoptosis was decreased and retinal function was preserved.
In the present study, the results showed that bortezomib had protective effects in retinal IR injury, both anatomically and functionally. No optimal treatment methods yet exist for several sight-threatening ophthalmic disorders involving the mechanisms of IR injury, and proteasome inhibition may be a potential strategy for managing these diseases. Our study has some limitations. First, bortezomib was administered before the induction of ischemia to ensure the onset of the drug’s effect, which would not happen in a clinical situation. However, the main purpose of our study was to evaluate the drug’s effect and possible mechanisms, so we still consider the results to be informative and referable. Second, due to the ubiquitous distribution of proteasomes, the systemic administration of proteasome inhibitors inevitably causes many unwanted adverse effects. Therefore, investigation of the heterogeneity between proteasomes in different organs is mandatory. These differences include the composition of subunits, protein structures, post-translational modification, and the associating partners of proteasomes , . The designation of organ-specific proteasome inhibitors theoretically provides better efficacy with increased safety. In conclusion, our study demonstrated that bortezomib successfully inhibited the activation of NF-κB and the induction of inflammatory cascades after retinal IR injury in a dose-dependent manner. Administration of bortezomib also reduced the oxidative stress in tissues and exerted protective effects on retinal tissue, both anatomically and functionally.
Body weight of the rats in different groups. The body weight of the rats didn’t differ significantly between the control and the treated groups both at 24 hours (A) and on Day 7 (B). The data are expressed as the mean ± SD of the mean in 3 rats for each group (bar graph). Statistical analysis by Kruskal Wallis H test with post hoc Dunn test.
The blood count of the rats in different groups. There was no statistically significant difference in the RBC count between the control and the treated groups both at 24 hours (A) and on Day 7 (B). Similarly, no statistically significant difference in WBC count was noted between the four groups both at 24 hours (C) and on Day 7 (D). The data are expressed as the mean ± SD of the mean in 3 rats for each group (bar graph). Statistical analysis by Kruskal Wallis H test with post hoc Dunn test.
Conceived and designed the experiments: FTC CMY CHY. Performed the experiments: FTC CMY CHY. Analyzed the data: FTC CMY CHY. Contributed reagents/materials/analysis tools: FTC CMY CHY. Wrote the paper: FTC CHY.
- 1. Zheng L, Gong B, Hatala DA, Kern TS (2007) Retinal ischemia and reperfusion causes capillary degeneration: similarities to diabetes. Invest Ophthalmol Vis Sci 48: 361–367.
- 2. Flammer J, Orgul S, Costa VP, Orzalesi N, Krieglstein GK, et al. (2002) The impact of ocular blood flow in glaucoma. Prog Retin Eye Res 21: 359–393.
- 3. Archer DB (1976) Tributary vein obstruction: pathogenesis and treatment of sequelae. Doc Ophthalmol 40: 339–360.
- 4. Cheung JY, Bonventre JV, Malis CD, Leaf A (1986) Calcium and ischemic injury. N Engl J Med 314: 1670–1676.
- 5. Osborne NN, Casson RJ, Wood JP, Chidlow G, Graham M, et al. (2004) Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog Retin Eye Res 23: 91–147.
- 6. Laskowski I, Pratschke J, Wilhelm MJ, Gasser M, Tilney NL (2000) Molecular and cellular events associated with ischemia/reperfusion injury. Ann Transplant 5: 29–35.
- 7. Piper HM, Meuter K, Schafer C (2003) Cellular mechanisms of ischemia-reperfusion injury. Ann Thorac Surg 75: S644–648.
- 8. Buchi ER, Suivaizdis I, Fu J (1991) Pressure-induced retinal ischemia in rats: an experimental model for quantitative study. Ophthalmologica 203: 138–147.
- 9. Hughes WF (1991) Quantitation of ischemic damage in the rat retina. Exp Eye Res 53: 573–582.
- 10. Jehle T, Wingert K, Dimitriu C, Meschede W, Lasseck J, et al. (2008) Quantification of ischemic damage in the rat retina: a comparative study using evoked potentials, electroretinography, and histology. Invest Ophthalmol Vis Sci 49: 1056–1064.
- 11. Sun MH, Pang JH, Chen SL, Han WH, Ho TC, et al. (2010) Retinal protection from acute glaucoma-induced ischemia-reperfusion injury through pharmacologic induction of heme oxygenase-1. Invest Ophthalmol Vis Sci 51: 4798–4808.
- 12. Katai N, Yoshimura N (1999) Apoptotic retinal neuronal death by ischemia-reperfusion is executed by two distinct caspase family proteases. Invest Ophthalmol Vis Sci 40: 2697–2705.
- 13. Dvoriantchikova G, Barakat D, Brambilla R, Agudelo C, Hernandez E, et al. (2009) Inactivation of astroglial NF-kappa B promotes survival of retinal neurons following ischemic injury. Eur J Neurosci 30: 175–185.
- 14. Gustavsson C, Agardh CD, Hagert P, Agardh E (2008) Inflammatory markers in nondiabetic and diabetic rat retinas exposed to ischemia followed by reperfusion. Retina 28: 645–652.
- 15. Dvoriantchikova G, Agudelo C, Hernandez E, Shestopalov VI, Ivanov D (2009) Phosphatidylserine-containing liposomes promote maximal survival of retinal neurons after ischemic injury. J Cereb Blood Flow Metab 29: 1755–1759.
- 16. Biermann J, Lagreze WA, Dimitriu C, Stoykow C, Goebel U (2010) Preconditioning with inhalative carbon monoxide protects rat retinal ganglion cells from ischemia/reperfusion injury. Invest Ophthalmol Vis Sci 51: 3784–3791.
- 17. Abraham E (2000) NF-kappaB activation. Crit Care Med 28: N100–104.
- 18. Valen G, Yan ZQ, Hansson GK (2001) Nuclear factor kappa-B and the heart. J Am Coll Cardiol 38: 307–314.
- 19. Serracino-Inglott F, Habib NA, Mathie RT (2001) Hepatic ischemia-reperfusion injury. Am J Surg 181: 160–166.
- 20. Chen YG, Zhang C, Chiang SK, Wu T, Tso MO (2003) Increased nuclear factor-kappa B p65 immunoreactivity following retinal ischemia and reperfusion injury in mice. J Neurosci Res 72: 125–131.
- 21. Wang J, Jiang S, Kwong JM, Sanchez RN, Sadun AA, et al. (2006) Nuclear factor-kappaB p65 and upregulation of interleukin-6 in retinal ischemia/reperfusion injury in rats. Brain Res 1081: 211–218.
- 22. Coux O, Tanaka K, Goldberg AL (1996) Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 65: 801–847.
- 23. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T (1994) The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell. 78: 773–785.
- 24. Wojcik C (2002) Regulation of apoptosis by the ubiquitin and proteasome pathway. J Cell Mol Med 6: 25–48.
- 25. Gilmore TD (2006) Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 25: 6680–6684.
- 26. Latanich CA, Toledo-Pereyra LH (2009) Searching for NF-kappaB-based treatments of ischemia reperfusion injury. J Invest Surg 22: 301–315.
- 27. Elliott PJ, Zollner TM, Boehncke WH (2003) Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med 81: 235–245.
- 28. Nencioni A, Grunebach F, Patrone F, Ballestrero A, Brossart P (2007) Proteasome inhibitors: antitumor effects and beyond. Leukemia 21: 30–36.
- 29. Williams AJ, Hale SL, Moffett JR, Dave JR, Elliott PJ, et al. (2003) Delayed treatment with MLN519 reduces infarction and associated neurologic deficit caused by focal ischemic brain injury in rats via antiinflammatory mechanisms involving nuclear factor-kappaB activation, gliosis, and leukocyte infiltration. J Cereb Blood Flow Metab 23: 75–87.
- 30. Pye J, Ardeshirpour F, McCain A, Bellinger DA, Merricks E, et al. (2003) Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury. Am J Physiol Heart Circ Physiol 284: H919–926.
- 31. Itoh M, Takaoka M, Shibata A, Ohkita M, Matsumura Y (2001) Preventive effect of lactacystin, a selective proteasome inhibitor, on ischemic acute renal failure in rats. J Pharmacol Exp Ther 298: 501–507.
- 32. Yu X, Kem DC (2010) Proteasome inhibition during myocardial infarction. Cardiovasc Res 85: 312–320.
- 33. Navon A, Ciechanover A (2009) The 26 S proteasome: from basic mechanisms to drug targeting. J Biol Chem 284: 33713–33718.
- 34. Chen FT, Liu YC, Yang CM, Yang CH (2012) Anti-inflammatory effect of the proteasome inhibitor bortezomib on endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci 53: 3682–3694.
- 35. Kisselev AF, van der Linden WA, Overkleeft HS (2012) Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol 19: 99–115.
- 36. Molineaux SM (2012) Molecular pathways: targeting proteasomal protein degradation in cancer. Clin Cancer Res 18: 15–20.
- 37. Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, et al. (2012) Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum 64: 493–503.
- 38. Williams AJ, Dave JR, Tortella FC (2006) Neuroprotection with the proteasome inhibitor MLN519 in focal ischemic brain injury: relation to nuclear factor kappaB (NF-kappaB), inflammatory gene expression, and leukocyte infiltration. Neurochem Int 49: 106–112.
- 39. Willmore WG, Storey KB (1996) Multicatalytic proteinase activity in turtle liver: responses to anoxia stress and recovery. Biochem Mol Biol Int 38: 445–451.
- 40. Kamikubo T, Hayashi T (1996) Changes in proteasome activity following transient ischemia. Neurochem Int 28: 209–212.
- 41. Bulteau AL, Lundberg KC, Humphries KM, Sadek HA, Szweda PA, et al. (2001) Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J Biol Chem 276: 30057–30063.
- 42. Asai A, Tanahashi N, Qiu JH, Saito N, Chi S, et al. (2002) Selective proteasomal dysfunction in the hippocampal CA1 region after transient forebrain ischemia. J Cereb Blood Flow Metab 22: 705–710.
- 43. Biermann J, Lagreze WA, Schallner N, Schwer CI, Goebel U (2011) Inhalative preconditioning with hydrogen sulfide attenuated apoptosis after retinal ischemia/reperfusion injury. Mol Vis 17: 1275–1286.
- 44. Hangai M, Yoshimura N, Honda Y (1996) Increased cytokine gene expression in rat retina following transient ischemia. Ophthalmic Res 28: 248–254.
- 45. Barone FC, Arvin B, White RF, Miller A, Webb CL, et al. (1997) Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. Stroke 28: 1233–1244.
- 46. Tezel G, Wax MB (2000) Increased production of tumor necrosis factor-alpha by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells. J Neurosci 20: 8693–8700.
- 47. Fontaine V, Mohand-Said S, Hanoteau N, Fuchs C, Pfizenmaier K, et al. (2002) Neurodegenerative and neuroprotective effects of tumor Necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci 22: RC216.
- 48. Jo N, Wu GS, Rao NA (2003) Upregulation of chemokine expression in the retinal vasculature in ischemia-reperfusion injury. Invest Ophthalmol Vis Sci 44: 4054–4060.
- 49. Springer TA (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76: 301–314.
- 50. Springer TA (1995) Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu Rev Physiol 57: 827–872.
- 51. Tsujikawa A, Ogura Y, Hiroshiba N, Miyamoto K, Kiryu J, et al. (1999) Retinal ischemia-reperfusion injury attenuated by blocking of adhesion molecules of vascular endothelium. Invest Ophthalmol Vis Sci 40: 1183–1190.
- 52. Hatchell DL, Wilson CA, Saloupis P (1994) Neutrophils plug capillaries in acute experimental retinal ischemia. Microvasc Res 47: 344–354.
- 53. Cho KJ, Kim JH, Park HY, Park CK (2011) Glial cell response and iNOS expression in the optic nerve head and retina of the rat following acute high IOP ischemia-reperfusion. Brain Res 1403: 67–77.
- 54. Hangai M, Yoshimura N, Hiroi K, Mandai M, Honda Y (1996) Inducible nitric oxide synthase in retinal ischemia-reperfusion injury. Exp Eye Res 63: 501–509.
- 55. Neufeld AH, Kawai S, Das S, Vora S, Gachie E, et al. (2002) Loss of retinal ganglion cells following retinal ischemia: the role of inducible nitric oxide synthase. Exp Eye Res 75: 521–528.
- 56. Chen B, Tang L (2011) Protective effects of catalase on retinal ischemia/reperfusion injury in rats. Exp Eye Res 93: 599–606.
- 57. Liu Y, Tang L, Chen B (2012) Effects of antioxidant gene therapy on retinal neurons and oxidative stress in a model of retinal ischemia/reperfusion. Free Radic Biol Med 52: 909–915.
- 58. Szabo ME, Droy-Lefaix MT, Doly M (1992) Modification of reperfusion-induced ionic imbalance by free radical scavengers in spontaneously hypertensive rat retina. Free Radic Biol Med 13: 609–620.
- 59. Szabo ME, Droy-Lefaix MT, Doly M, Carre C, Braquet P (1991) Ischemia and reperfusion-induced histologic changes in the rat retina. Demonstration of a free radical-mediated mechanism. Invest Ophthalmol Vis Sci 32: 1471–1478.
- 60. Zhao ZQ (2004) Oxidative stress-elicited myocardial apoptosis during reperfusion. Curr Opin Pharmacol 4: 159–165.
- 61. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, et al. (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799–1805.
- 62. Qin ZH, Chen RW, Wang Y, Nakai M, Chuang DM, et al. (1999) Nuclear factor kappaB nuclear translocation upregulates c-Myc and p53 expression during NMDA receptor-mediated apoptosis in rat striatum. J Neurosci 19: 4023–4033.
- 63. Liang ZQ, Li YL, Zhao XL, Han R, Wang XX, et al. (2007) NF-kappaB contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53. Brain Res 1145: 190–203.
- 64. Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293–299.
- 65. Gomes AV, Young GW, Wang Y, Zong C, Eghbali M, et al. (2009) Contrasting proteome biology and functional heterogeneity of the 20 S proteasome complexes in mammalian tissues. Mol Cell Proteomics 8: 302–315.